Introduction
From a pathophysiological standpoint, type 2 diabetes, accounting for almost 90% of diabetic patients, is a progressive disease causing abnormal carbohydrate, lipid, and protein metabolism associated with insulin resistance and impaired insulin secretion.(1) Insulin resistance is involved in disease progression and is considered a major component of diabetes-associated complications such as blindness, heart diseases, kidney problems, nerve damage, and erectile dysfunction.(2, 3) Despite current therapies, a significant number of patients with type 2 diabetes are unable to reach the glycemic target.(4) Therefore, glucose-lowering and disease-modifying drugs, working through unconventional targets, are still required for the treatment of type 2 diabetes.
After protein kinases and G protein-coupled receptors, voltage-gated ion channels represent the largest group of signaling structures encoded by the human genome. Glucose-stimulated insulin secretion from pancreatic β-cells is regulated by a series of electrogenic events leading to insulin exocytosis.(5) In β-cells, the release of insulin can be associated to the activation of 3 types of potassium channels: ATP-sensitive potassium channel (KATP), calcium-activated potassium channels (KCa), and voltage-gated potassium (Kv) channels.(6) For decades, modulators of KATP channels have been used as oral treatment for type 2 diabetes. However, increasing evidence has demonstrated that modulation of Kv channels, including Kv1.3, Kv1.4, Kv2.1, and KCachannels like KCa3.1, could represent attractive targets for the management of type 2 diabetes. One major physiological function of these channels is the maintenance of a negative membrane potential, which facilitates sustained Ca 2+ signaling during β-cell activation by providing the electrical driving force for Ca 2+ entry through voltage-independent Ca 2+ channels. Recently, we have isolated, from the venom of the Vietnamese snake Naja kaouthia, a peptide that potently stimulated insulin secretion in pancreatic β-cells, i.e., INS-1E.(18) Its characterization showed that it was a 60-amino acid peptide known as cardiotoxin-I (CTX-I).
Structural homology with known insulinotropic peptide toxins suggested that [Lys 52 ]CTX-I41-60could act as a potassium channel blocker. In the present study, we have rationally designed an equipotent and shorter version of CTX-I using molecular modeling and demonstrated that the mechanism underlying its insulinotropic activity is clearly related to the inhibition of potassium channels.
Results and Discussion

Molecular Modeling
Numerous potassium channel modulators have been engineered using natural peptides isolated from scorpion, snake,and sea anemone venoms as chemical templates.(17) Most polypeptide toxins bind with high affinity to a cavity at the entrance of K + channel pores,(17) which are formed by the juxtaposition of 4 protein units identified as A, B, C, and D. These toxins, generally characterized by three well-conserved disulfide bridges, mediate the interaction with the channel pore using a conserved three-residue motif that plays a crucial role in establishing the toxin-blocking mechanism.(17) This motif is comprised of conserved amino acids or similar property side chains pointing toward the interior of the pore. The toxin motif properties are defined as follows: (1) a strictly conserved lysine at the center of the toxin interface, (2) an asparagine or polar residue at one end of the toxin, and (3) an arginine or positively charged residue at the opposite end (Figures 1A and 2A) . This conserved motif is not always obvious and can sometimes be difficult to observe structurally, much like in BgK (PDB entry 1BGK) and ShK (PDB entry 1ROO), two toxins that were shown to interact with potassium channels in a similar fashion ( Figure 1B Figure 2C ,D). Our results demonstrate that the charged/hydrophobic surface repartition is critical for the optimal interaction with various K + channels. While potassium channel blocking is achieved through a conserved consensus sequence, binding specificity is achieved by subtle differences in amino acid composition. We recently reported that cardiotoxin-I (CTX-I), isolated from the Naja kaouthia snake venom, can modulate insulin secretion from INS-1E cells without affecting cell viability and integrity. (18)A sequence and structure alignment between this 60-amino acid containing three-finger toxin and other K + channel blockers did not reveal any similarity ( Figure 1A Figure 3A When comparing the CTX-I three-residue motif with the above-mentioned CHT interface, at least 8 of the 10 surface interactions are conserved, suggesting the presence of a similar binding interface with Kv and KCa channels (Table 1 and Figure 3C ,D). As presented in 
Cytotoxic Activity of CTX-I and Related Analogues
Most cardiotoxins (CTXs) are known to exert cytotoxic activities through the necrotic and apoptotic pathways by binding to zwitterionic phospholipids through hydrophobic interactions(23, 24) and to anionic glycosaminoglycans via electrostatic interactions. (25) Cytotoxic activities of CTX-I and its related derivatives on INS-1E cells. Statistical comparisons were performed by ANOVA followed by a Dunnett's multiple comparison test, and differences were considered significant when *P < 0.05, **P < 0.01, and ***P < 0.001.
Insulinotropic Action of CTX-I and Related Analogues
Our understanding of the mechanisms behind insulin secretion remains somewhat elusive. Initial experiment revealed that CTX-I and its shorter unmodified fragment, i.e., CTX-I41-60, increased the intracellular Ca 2+ mobilization with a similar potency (pEC50 = 8.85 ± 0.17 versus 8.67 ± 0.15, respectively) ( Figure 5A ). However, as depicted in Figure 5A ,B, CTX-I41-60 was significantly less efficient compared to its full-length counterpart. Interestingly, and in accordance with our in silico predictive model, introduction of a Lys residue at position 52,
i.e., [Lys 52 ]CTX-I41-60, completely restored the Ca 2+ release activity ( Figure 5A Statistical comparisons were performed by ANOVA followed by a Dunnett's multiple comparison test, and differences were considered significant when *P < 0.05, **P < 0.01, ***P < 0.001, Figure 6A ,B). Therefore, we conclude that these peptides do not exert their action through GLP-1 receptor activation. comparisons were performed by One-Way ANOVA, and differences were considered significant when *P < 0.05, **P < 0.01, and ***P < 0.001. influx and lead to an increase in insulin secretion, as previously reported.(9) Specificity of our newly discovered compound will be further investigated through electrophysiology studies. However, it is likely that this newly designed polypeptide toxin is acting through Kv channels to induce insulin secretion in INS-1E cells. ]CTX-I41-60. Statistical comparisons were performed by One-Way ANOVA, and differences were considered significant when *P < 0.05, **P < 0.01, and ***P < 0.001.
Elevation of intracellular Ca
Conclusion
Further investigations are still needed to confirm the physiological target of CTX-I and its related analogue [Lys 52 ]CTX-I41-60. The discovery of a reduced-size peptide triggering insulin release through a purported interaction with Kv channels at the cell membrane could represent a new tool to improve our understanding of insulin release, and our knowledge regarding specific interaction related to Kv blockage and specificity. Finally, this compound might be a key step in the development of a new therapeutic strategy for the treatment of type 2 diabetes.
Experimental Section
Materials
All Fmoc-protected amino acids and benzotriazol-1-yl-oxy-tris ( were characterized by a purity higher than 95% (Table 2) by analytical RP-HPLC and MALDI-TOF analysis (Table 2) . 
Cell Culture
The rat pancreatic β-cell line (INS-1E) was a generous gift from Pr. Pierre Maechler (University of Geneva, Switzerland). Cells were maintained in RPMI-1640 culture medium supplemented with 10 mM HEPES, 10% heat-inactivated fetal bovine serum (FBS), 2 mM glutamine, 1 mM sodium pyruvate, 50 μM 2-mercaptoethanol, and 100 U/mL of penicillin and streptomycin. Cells, grown as a monolayer at 37 °C in a humidified atmosphere of 5% CO2, were passaged by trypsinization once cells reached confluence. Following a 30 min incubation at 37 °C in a glucose-free KRBH buffer, cells were washed once with glucose-free KRBH buffer and then incubated at 37 °C for 2 h with the appropriate peptide in the presence (20 mM) or absence of glucose. Incubation was stopped by placing the plates on ice, and cell culture media were then collected to quantify secreted insulin using a commercially available RIA Kit (Millipore, St. Charles, MI, USA) following the manufacturer's protocol with rat insulin as the standard. RbCl in culture medium (0.02 μCi/mL) Then, to each well, 100 μL of low-potassium buffer (135 mM NaCl, 4.6 mM KCl, 1 mM CaCl2, 2 mM MgCl2, 0.2% bovine serum albumin, and 10 mM HEPES, pH 7.4) with or without peptide was added, and incubation resumed for 30 min at 37 °C. At the end of this period, the medium was replaced with 200 μL of high-potassium buffer (140 mM KCl, 1 mM CaCl2, 2 mM MgCl2, 0.2% bovine serum albumin, and 10 mM HEPES, pH 7.4), with or without peptide, and 
Intracellular Calcium Mobilization
]i = Kd × [(R -Rmin)/(Rmax -R)]
Cell Viability
Statistical Analysis
Functional experiments were performed at least in triplicate and data, expressed as mean ± SEM, were analyzed with the Prism software (GraphPad Software, San Diego, CA, USA).
Statistical comparisons were performed by ANOVA followed by a Dunnett's multiple comparison test, and differences were considered significant when *P < 0.05, **P < 0.01, and ***P < 0.001.
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